Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GLSINASDAQ:MCRBNASDAQ:TLSANASDAQ:VACC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGLSIGreenwich LifeSciences$10.04+1.6%$9.56$8.06▼$17.19$134.08M1.6343,502 shs31,423 shsMCRBSeres Therapeutics$11.36+4.6%$8.27$6.53▼$30.60$103.65M2.75134,471 shs107,170 shsTLSATiziana Life Sciences$1.54-1.9%$1.48$0.63▼$1.91$176.44M-0.05475,946 shs179,781 shsVACCVaccitech$0.92-2.6%$1.57$1.64▼$5.10$35.51M-0.4244,643 shs16,172 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGLSIGreenwich LifeSciences0.00%+11.62%+6.42%+13.65%-39.91%MCRBSeres Therapeutics0.00%+24.78%+56.40%-11.29%-19.10%TLSATiziana Life Sciences0.00%-3.75%+9.22%+63.26%+86.67%VACCVaccitech0.00%+0.56%-8.80%+21.20%-35.75%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGLSIGreenwich LifeSciences1.5034 of 5 stars3.50.00.00.00.63.30.0MCRBSeres Therapeutics3.5634 of 5 stars2.92.00.04.62.80.80.0TLSATiziana Life Sciences0.6752 of 5 stars0.05.00.00.00.61.70.0VACCVaccitechN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGLSIGreenwich LifeSciences 3.00Buy$39.00288.64% UpsideMCRBSeres Therapeutics 1.75Reduce$73.67548.76% UpsideTLSATiziana Life Sciences 0.00N/AN/AN/AVACCVaccitech 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest VACC, TLSA, MCRB, and GLSI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2025MCRBSeres TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$1.25 ➝ $6.004/21/2025GLSIGreenwich LifeSciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$38.00 ➝ $39.00(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGLSIGreenwich LifeSciencesN/AN/AN/AN/A$0.19 per shareN/AMCRBSeres Therapeutics$126.32M0.78N/AN/A$1.61 per share7.05TLSATiziana Life SciencesN/AN/AN/AN/A$0.04 per shareN/AVACCVaccitech$13.42M2.64$0.05 per share19.30$6.52 per share0.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGLSIGreenwich LifeSciences-$15.79M-$1.26N/AN/AN/AN/A-450.87%-333.18%8/12/2025 (Estimated)MCRBSeres Therapeutics$140K-$4.60N/AN/AN/AN/A-41,084.76%-55.87%8/12/2025 (Estimated)TLSATiziana Life Sciences-$11.86MN/A0.00∞N/AN/AN/AN/A8/5/2025 (Estimated)VACCVaccitech$5.34M-$1.43N/AN/AN/A-409.18%-23.41%-20.85%N/ALatest VACC, TLSA, MCRB, and GLSI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2025Q1 2025GLSIGreenwich LifeSciences-$0.24-$0.25-$0.01-$0.25N/AN/A5/7/2025Q1 2025MCRBSeres Therapeutics-$0.67-$2.24-$1.57$3.75$10.00 millionN/A4/15/2025Q4 2024GLSIGreenwich LifeSciences-$0.21-$0.61-$0.40-$0.61N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGLSIGreenwich LifeSciencesN/AN/AN/AN/AN/AMCRBSeres TherapeuticsN/AN/AN/AN/AN/ATLSATiziana Life SciencesN/AN/AN/AN/AN/AVACCVaccitechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGLSIGreenwich LifeSciencesN/A1.911.91MCRBSeres TherapeuticsN/A2.112.11TLSATiziana Life SciencesN/A1.021.02VACCVaccitechN/A15.2615.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGLSIGreenwich LifeSciences4.16%MCRBSeres Therapeutics59.34%TLSATiziana Life SciencesN/AVACCVaccitech26.13%Insider OwnershipCompanyInsider OwnershipGLSIGreenwich LifeSciences51.67%MCRBSeres Therapeutics4.70%TLSATiziana Life Sciences39.82%VACCVaccitech6.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGLSIGreenwich LifeSciences313.37 million6.46 millionNot OptionableMCRBSeres Therapeutics3308.73 million8.32 millionOptionableTLSATiziana Life Sciences8116.85 million70.32 millionOptionableVACCVaccitech3338.55 million36.23 millionNot OptionableVACC, TLSA, MCRB, and GLSI HeadlinesRecent News About These CompaniesVTP-500 by Barinthus Biotherapeutics for Middle East Respiratory Syndrome (MERS): Likelihood of ApprovalDecember 31, 2024 | pharmaceutical-technology.comPReal-World Data on the RSV Vaccine for Older AdultsNovember 12, 2024 | msn.com10 Startups Founded Out Of Oxford UniversityNovember 5, 2024 | techround.co.ukTTen things to know about new R21 malaria vaccine Nigeria receivedOctober 18, 2024 | premiumtimesng.comPNigeria: Ten Things to Know About New R21 Malaria Vaccine Nigeria ReceivedOctober 18, 2024 | allafrica.comBarinthus Bio completes enrolment in hepatitis B and prostate cancer vaccine trialsOctober 2, 2024 | finance.yahoo.comBuy Rating Affirmed on Barinthus Biotherapeutics Amid Promising Clinical Trials and Therapeutic AdvancesOctober 1, 2024 | markets.businessinsider.comBarinthus Bio Completes Enrollment for Phase 2b HBV003 Clinical Trial in Chronic Hepatitis B and Phase 1 PCA001 Clinical Trial in Prostate CancerOctober 1, 2024 | markets.businessinsider.comStrong Buy Rating for Barinthus Biotherapeutics Amid Promising Trials in Celiac and Hepatitis B TherapiesSeptember 26, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for Barinthus Biotherapeutics Amid Promising Clinical AdvancementsAugust 12, 2024 | markets.businessinsider.comBRNS Stock Earnings: Barinthus Biotherapeutics Misses EPS for Q2 2024August 9, 2024 | markets.businessinsider.comGiving RSV and Flu Vaccines Together Led to Adequate Immune ResponsesAugust 7, 2024 | medpagetoday.comMHow real are the threats to the US dollar?July 31, 2024 | uk.finance.yahoo.comZoster Vaccine Market to Reach $9.1 Billion by 2033; Increasing Cases of Herpes Zoster Drives the Market's GrowthJuly 29, 2024 | finance.yahoo.comGoogle invests in UK vaccine pioneer VaccitechJuly 26, 2024 | pharmaphorum.comPBarinthus Bio to Present VTP-300 Clinical Data Updates at EASL Congress 2024May 22, 2024 | markets.businessinsider.comBuy Rating for Barinthus Biotherapeutics Backed by Strong Financials and Promising Clinical TrialsMay 17, 2024 | markets.businessinsider.comReal reasons Nigeria still missing out on malaria vaccine rolloutMay 11, 2024 | premiumtimesng.comPChutes & Ladders—BridgeBio oncology execs take the reins of new spinoutMay 3, 2024 | fiercebiotech.comFNews - Leon HooftmanMay 1, 2024 | thepharmaletter.comTNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVACC, TLSA, MCRB, and GLSI Company DescriptionsGreenwich LifeSciences NASDAQ:GLSI$10.04 +0.16 (+1.57%) As of 07/3/2025 03:12 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.Seres Therapeutics NASDAQ:MCRB$11.36 +0.50 (+4.56%) Closing price 07/3/2025 03:57 PM EasternExtended Trading$11.94 +0.58 (+5.11%) As of 07/3/2025 04:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.Tiziana Life Sciences NASDAQ:TLSA$1.54 -0.03 (-1.91%) As of 07/3/2025 03:23 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.Vaccitech NASDAQ:VACCVaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious and autoimmunity diseases, and cancers. The company's therapeutic programs include VTP-300, which is in Phase 2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1b/2 clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
